MedTrace Logo

L-arginine add-on Therapy in Patients With Schizophrenia

NCT02398279 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-03-25

No results posted yet for this study

Summary

This study evaluates the addition of L-Arginine to the usual regimen in the treatment of schizophrenia in adults. As a requisite of crossover design, half of the participants started with L-Arginine and the other half with placebo and switched over after a three weeks use and one week of a washout period.

Conditions

Interventions

DIETARY_SUPPLEMENT

L-Arginine

Experimental supplement

OTHER

Placebo

Placebo capsules in the same color and shape with the experimental supplement

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Kazım M Yazıcı, MD · Hacettepe University Faculty of Medicine Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398279 on ClinicalTrials.gov